Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Prader–Willi Syndrome in 21 Major Markets
Prader–Willi syndrome (PWS) is a genetic disease caused by the loss of function of several genes in a particular region of chromosome 15, affecting many parts of the body. These genes provide instructions for making molecules called small nucleolar RNAs (snRNAs) which have a variety of functions. PWS initially comprises weak muscle tone (hypotonia), feeding difficulties, poor growth and delayed development, usually persisting for 12 months after birth. Around the age of 2 years, this is followed by weight gain and obesity due to hyperphagia, hypogonadism and global developmental delay.
This report provides the current prevalent population for PWS across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Denmark, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, PWS patients grouped by various features, symptoms and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for PWS include:
• Cardiovascular problems
• Obstructive sleep apnoea and respiratory disorders
• Type 2 diabetes mellitus
• Autism spectrum disorder behavioural characteristics
• Seizures
• Hip dysplasia
• Scoliosis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global PWS market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of PWS and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of PWS patients.
• Identification of PWS patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of PWS patients.
Epiomic Epidemiology Series: Prader–Willi Syndrome in 21 Major Markets 2018–2028
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• ADDITIONAL DATA AVAILABLE ON REQUEST
• TOP-LINE PREVALENCE FOR PRADER–WILLI SYNDROME
• FEATURES OF PRADER–WILLI SYNDROME PATIENTS
• COMORBIDITIES OF PRADER–WILLI SYNDROME PATIENTS
• CARDIOVASCULAR
• SKELETAL
• PSYCHOLOGICAL
• OCULAR
• OTHER
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Prevalence of PWS, total (000s)
• Table 2. Prevalence of PWS, males (000s)
• Table 3. Prevalence of PWS, females (000s)
• Table 4. PWS patients by nutritional phase, total (000s)
• Table 5. PWS patients by type of mutation, total (000s)
• Table 6. PWS patients by IQ level, total (000s)
• Table 7. PWS patients with hypertension, total (000s)
• Table 8. PWS patients with cardiovascular problems, total (000s)
• Table 9. PWS patients with scoliosis, total (000s)
• Table 10. PWS patients with hip dysplasia, total (000s)
• Table 11. PWS patients with autism spectrum disorder behavioural characteristics, total (000s)
• Table 12. PWS patients with psychotic disorders, total (000s)
• Table 13. PWS patients with strabismus, total (000s)
• Table 14. PWS patients with eye abnormalities, total (000s)
• Table 15. PWS patients with type 2 diabetes mellitus, total (000s)
• Table 16. PWS patients with obstructive sleep apnoea / respiratory problems, total (000s)
• Table 17. PWS patients with seizures, total (000s)
• Table 18. PWS patients with short stature, total (000s)
• Table 19. PWS patients with hypopigmentation, total (000s)
• Table 20. Abbreviations and acronyms used in the report
• Table 21. USA prevalence of PWS by 5-yr age cohort, males (000s)
• Table 22. USA prevalence of PWS by 5-yr age cohort, females (000s)
• Table 23. Canada prevalence of PWS by 5-yr age cohort, males (000s)
• Table 24. Canada prevalence of PWS by 5-yr age cohort, females (000s)
• Table 25. France prevalence of PWS by 5-yr age cohort, males (000s)
• Table 26. France prevalence of PWS by 5-yr age cohort, females (000s)
• Table 27. Germany prevalence of PWS by 5-yr age cohort, males (000s)
• Table 28. Germany prevalence of PWS by 5-yr age cohort, females (000s)
• Table 29. Italy prevalence of PWS by 5-yr age cohort, males (000s)
• Table 30. Italy prevalence of PWS by 5-yr age cohort, females (000s)
• Table 31. Spain prevalence of PWS by 5-yr age cohort, males (000s)
• Table 32. Spain prevalence of PWS by 5-yr age cohort, females (000s)
• Table 33. UK prevalence of PWS by 5-yr age cohort, males (000s)
• Table 34. UK prevalence of PWS by 5-yr age cohort, females (000s)
• Table 35. Poland prevalence of PWS by 5-yr age cohort, males (000s)
• Table 36. Poland prevalence of PWS by 5-yr age cohort, females (000s)
• Table 37. Netherlands prevalence of PWS by 5-yr age cohort, males (000s)
• Table 38. Netherlands prevalence of PWS by 5-yr age cohort, females (000s)
• Table 35. Belgium prevalence of PWS by 5-yr age cohort, males (000s)
• Table 36. Belgium prevalence of PWS by 5-yr age cohort, females (000s)
• Table 37. Denmark prevalence of PWS by 5-yr age cohort, males (000s)
• Table 38. Denmark prevalence of PWS by 5-yr age cohort, females (000s)
• Table 39. Russia prevalence of PWS by 5-yr age cohort, males (000s)
• Table 40. Russia prevalence of PWS by 5-yr age cohort, females (000s)
• Table 41. Turkey prevalence of PWS by 5-yr age cohort, males (000s)
• Table 42. Turkey prevalence of PWS by 5-yr age cohort, females (000s)
• Table 43. Japan prevalence of PWS by 5-yr age cohort, males (000s)
• Table 44. Japan prevalence of PWS by 5-yr age cohort, females (000s)
• Table 45. China prevalence of PWS by 5-yr age cohort, males (000s)
• Table 46. China prevalence of PWS by 5-yr age cohort, females (000s)
• Table 47. South Korea prevalence of PWS by 5-yr age cohort, males (000s)
• Table 48. South Korea prevalence of PWS by 5-yr age cohort, females (000s)
• Table 49. India prevalence of PWS by 5-yr age cohort, males (000s)
• Table 50. India prevalence of PWS by 5-yr age cohort, females (000s)
• Table 51. Australia prevalence of PWS by 5-yr age cohort, males (000s)
• Table 52. Australia prevalence of PWS by 5-yr age cohort, females (000s)
• Table 53. Brazil prevalence of PWS by 5-yr age cohort, males (000s)
• Table 54. Brazil prevalence of PWS by 5-yr age cohort, females (000s)
• Table 55. Mexico prevalence of PWS by 5-yr age cohort, males (000s)
• Table 56. Mexico prevalence of PWS by 5-yr age cohort, females (000s)
• Table 57. Argentina prevalence of PWS by 5-yr age cohort, males (000s)
• Table 58. Argentina prevalence of PWS by 5-yr age cohort, females (000s)
